Biomarkers for the Clinical Diagnosis of Alzheimer's Disease: Metabolomics Analysis of Brain Tissue and Blood
- PMID: 34366852
- PMCID: PMC8333692
- DOI: 10.3389/fphar.2021.700587
Biomarkers for the Clinical Diagnosis of Alzheimer's Disease: Metabolomics Analysis of Brain Tissue and Blood
Abstract
With an increase in aging populations worldwide, age-related diseases such as Alzheimer's disease (AD) have become a global concern. At present, a cure for neurodegenerative disease is lacking. There is an urgent need for a biomarker that can facilitate the diagnosis, classification, prognosis, and treatment response of AD. The recent emergence of highly sensitive mass-spectrometry platforms and high-throughput technology can be employed to discover and catalog vast datasets of small metabolites, which respond to changed status in the body. Metabolomics analysis provides hope for a better understanding of AD as well as the subsequent identification and analysis of metabolites. Here, we review the state-of-the-art emerging candidate biomarkers for AD.
Keywords: alzheimer’s disease; brain and blood samples; candidate diagnosis biomarker; clinical screening; metabolomics.
Copyright © 2021 Wang, Sun, Luo, Peng, Li, Yang, Wang and Kuang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures





Similar articles
-
Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid.J Neurosci Res. 2017 Oct;95(10):2005-2024. doi: 10.1002/jnr.24048. Epub 2017 Mar 16. J Neurosci Res. 2017. PMID: 28301062 Review.
-
High-Throughput Metabolomics for Discovering Potential Biomarkers and Identifying Metabolic Mechanisms in Aging and Alzheimer's Disease.Front Cell Dev Biol. 2021 Feb 25;9:602887. doi: 10.3389/fcell.2021.602887. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33718349 Free PMC article.
-
Alteration of Metabolic Profile and Potential Biomarkers in the Plasma of Alzheimer's Disease.Aging Dis. 2020 Dec 1;11(6):1459-1470. doi: 10.14336/AD.2020.0217. eCollection 2020 Dec. Aging Dis. 2020. PMID: 33269100 Free PMC article.
-
Characterizing Alzheimer's disease through metabolomics and investigating anti-Alzheimer's disease effects of natural products.Ann N Y Acad Sci. 2017 Jun;1398(1):130-141. doi: 10.1111/nyas.13385. Epub 2017 Jun 20. Ann N Y Acad Sci. 2017. PMID: 28632966 Review.
-
Metabolomics in Alzheimer's disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology.J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Dec 15;1071:75-92. doi: 10.1016/j.jchromb.2017.02.008. Epub 2017 Feb 6. J Chromatogr B Analyt Technol Biomed Life Sci. 2017. PMID: 28189423 Review.
Cited by
-
Essential New Complexity-Based Themes for Patient-Centered Diagnosis and Treatment of Dementia and Predementia in Older People: Multimorbidity and Multilevel Phenomenology.J Clin Med. 2024 Jul 18;13(14):4202. doi: 10.3390/jcm13144202. J Clin Med. 2024. PMID: 39064242 Free PMC article. Review.
-
Monitoring drug Efficacy through Multi-Omics Research initiative in Alzheimer's Disease (MEMORI-AD): A protocol for a multisite exploratory prospective cohort study on the drug response-related clinical, genetic, microbial and metabolomic signatures in Filipino patients with Alzheimer's disease.BMJ Open. 2024 Nov 27;14(11):e078660. doi: 10.1136/bmjopen-2023-078660. BMJ Open. 2024. PMID: 39608999 Free PMC article.
-
Associations Between Metabolomics Findings and Brain Hypometabolism in Mild Cognitive Impairment and Alzheimer's Disease.Curr Alzheimer Res. 2024;21(9):679-689. doi: 10.2174/0115672050350196250110092338. Curr Alzheimer Res. 2024. PMID: 39878109
-
Quantitative analysis of targeted lipidomics in the hippocampus of APP/PS1 mice employing the UHPLC-MS/MS method.Front Aging Neurosci. 2025 Jul 7;17:1561831. doi: 10.3389/fnagi.2025.1561831. eCollection 2025. Front Aging Neurosci. 2025. PMID: 40693114 Free PMC article.
-
Blood-Based Biomarkers for Alzheimer's Disease Diagnosis and Progression: An Overview.Cells. 2022 Apr 17;11(8):1367. doi: 10.3390/cells11081367. Cells. 2022. PMID: 35456047 Free PMC article. Review.
References
-
- Albert M. S., DeKosky S. T., Dickson D., Dubois B., Feldman H. H., Fox N. C., et al. (2011). The Diagnosis of Mild Cognitive Impairment Due to Alzheimer’s Disease: Recommendations From the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease. Alzheimers Dement. 7, 270–279. 10.1016/j.jalz.2011.03.008 - DOI - PMC - PubMed
-
- Aluise C. D., Sowell R. A., Butterfield D. A. (2008). Peptides and Proteins in Plasma and Cerebrospinal Fluid as Biomarkers for the Prediction, Diagnosis, and Monitoring of Therapeutic Efficacy of Alzheimer’s Disease. Biochim. Biophys. Acta 1782, 549–558. 10.1016/j.bbadis.2008.07.008 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources